News|Articles|August 8, 2024
Biopharmaceutical Frontiers
Author(s)Solvias
Daniel Galbraith, Chief Scientific Officer (CSO) of Solvias provided a comprehensive picture to Pharmaceutical Technology of the current landscape of cell and gene therapy advancements. The discussion covers important regulatory guidance, technological landmarks, and how Solvias is impacting the current market.
Related Content
Trending on Pharmaceutical Technology
1
PharmTech Weekly Roundup—June 5, 2026
2
A Pharma Manufacturing Blueprint from Delaware’s Innovation Vision
3
EMA Collaborates with African Regulators on Ebola Treatments
4
Renewing Prosaic Generics for Cancer Treatment
5